9 ASX 200 shares earning strengthened buy ratings this week
Meanwhile, brokers have indicated continued confidence in several ASX 200 shares this week.
Let's take a look.
Santos Ltd (ASX: STO)
The Santos share price is $8.55, up 0.3% today.
Over the past month, this ASX 200 energy share has risen 12%.
Citi renewed its buy rating on Santos shares on Tuesday.
The broker raised its 12-month price target from $9 to $9.35.
This suggests a potential 9% upside ahead.
Goodman Group (ASX: GMG)
The Goodman Group share price is $26.92, down 0.9% today.
Over the past month, this ASX 200 property share has fallen 10%.
UBS reiterated its buy rating on Goodman shares today with a price target of $33.66.
This implies potential capital gains of 25% ahead.
Telstra Group Ltd (ASX: TLS)
The Telstra share price is $4.81, up 0.5% today.
Over the past month, this ASX telco share has declined 4%.
Citi renewed its buy recommendation with a 12-month price target of $5.25 this week.
This implies a potential 10% upside ahead.
Pls Group Ltd (ASX: PLS)
The PLS Group share price is $4.84, down 3.5% today.
Over the past month, this ASX 200 lithium share has lifted 2%.
Citi renewed its buy rating on PLS Group shares on Wednesday.
The broker increased its target price from $5 to $5.70.
This implies potential capital growth of 17% over the next year.
AMP Ltd (ASX: AMP)
The AMP share price is $2.48, down 0.4% on Thursday.
Over the past month, this ASX 200 financial share has risen 5%.
Jefferies renewed its buy rating on AMP shares yesterday.
The broker raised its target from $2.55 to $2.77.
This implies potential capital growth of 12% over the next year.
Life360 Inc (ASX: 360)
The Life360 share price is $19.43, down 1% today.
Over the past month, this ASX 200 tech share has fallen 34%.
Citi renewed its buy rating on Life360 shares with a $28.80 target this week.
This suggests a potential 49% upside ahead.
Pro Medicus Ltd (ASX: PME)
This ASX 200 healthcare share has fallen 6% over the past month.
Citi reiterated its buy rating on Pro Medicus shares today.
The broker decreased its price target from $240 to $225.
This still implies a healthy potential upside of 35% ahead.
Pro Medicus is one of 40 ASX shares going ex-dividend this week.
Sigma Healthcare Ltd (ASX: SIG)
The Sigma Healthcare share price is $2.65, down 0.9% today.
Over the past month, this ASX 200 healthcare share has fallen 11%.
Macquarie renewed its buy rating on Sigma Healthcare shares on Monday.
The broker has a 12-month price target of $3.20.
This suggests a potential 21% upside ahead.
ANZ Group Holdings Ltd (ASX: ANZ)
The ANZ share price is $36.39, down 1.1% today.
Over the past month, this ASX 200 bank share has fallen 2%.
Citi reiterated its buy rating on ANZ shares with a $39.25 target this week.
This implies a potential 7% upside ahead.
ASX 200 bank shares weakened last month amid investor concerns over a housing credit downturn.
ANZ shares fared best as the bank continues to benefit from a reset under CEO Nuno Matos.
The post 9 ASX 200 shares earning strengthened buy ratings this week appeared first on The Motley Fool Australia.
Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goodman Group, Jefferies Financial Group, Life360, and Macquarie Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Life360 and Telstra Group. The Motley Fool Australia has recommended Goodman Group, Macquarie Group, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026